Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Komal Jhaveri, Eric Paul Winer, Elgene Lim, Jose AlejandroPerez Fidalgo, Meritxell Bellet, Ingrid Alina Mayer, Valentina Boni, Jaymin M Patel, Aditya Bardia, Jose Manuel Garcia, Peter Kabos, Mary Gates, Ya-Chi Chen, Jill Fredrickson, Xiaojing Wang, Lori Sickels Friedman, Jill Spoerke, Steven Gendreau, Ciara Metcalfe, Lichuan Liu, Ching-Wei Chang, Sharareh Monemi, Monica Gonzalez, Ursula McCurry, Sandra Milan, Eric William Humke, Sherene Loi
Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Garvan Institute of Medical Research, Hospital Clínico Universitario de Valencia, Centro de Investigación Biomédica en Red de Cáncer, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Vanderbilt University Medical Center, Hospital Universitario HM Sanchinarro, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, University of Colorado Denver, Genentech, Peter MacCallum Cancer Centre
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4251387620